| D008107 |
Liver Diseases |
Pathological processes of the LIVER. |
Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions |
|
| D008111 |
Liver Function Tests |
Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. |
Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function |
|
| D008657 |
Metabolic Clearance Rate |
Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. |
Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance |
|
| D001944 |
Breath Tests |
Any tests done on exhaled air. |
Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000632 |
Aminopyrine |
A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS. |
Amidophenazon,Aminophenazone,Dimethylaminophenazone,Dipyrine,Amidazophen,Amidophen,Amidopyrine,Aminofenazone,Dimethyl-N-aminoantipyrine,Dimethylaminoantipyrine,Eufibron,Dimethyl N aminoantipyrine |
|
| D000983 |
Antipyrine |
An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) |
Phenazone,Anodynin,Pyramidone |
|
| D001711 |
Biotransformation |
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II. |
|
|